A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Advanced Solid Tumor
Melanoma
Metastasis
Pleural Mesothelioma
Renal Cell Carcinoma
MSI-High
Mismatch Repair Deficiency
Colorectal Cancer
Hepatocellular Carcinoma
Hepatocellular Cancer
Renal Cell Cancer
Kidney Cancer
Skin Cancer
Non Small Cell Lung Cancer
NSCLC
Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
ALK Genomic Tumor Aberrations

Interventions

DRUG: Alintegimod
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

7 Hills Pharma, LLC